All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation
During the 7th World Congress on Controversies in Multiple Myeloma (COMy), the Multiple Myeloma Hub hosted its first Satellite Symposium: Should 'cure' be the goal for multiple myeloma? Vincent Rajkumar, Mayo Clinic, Rochester, US, discussed: Treating elderly and frail patients with MM: Cure versus disease control.
Welcome to the Multiple Myeloma Hub Satellite Symposium.
Please take a moment to complete the survey and answer the following question to help us gauge your current understanding of the treatment of multiple myeloma.
In this presentation, Rajkumar discusses the current standard of treatment for elderly, frail patients (VRd−bortezomib, lenalidomide, dexamethasone) and regimens that are currently being tested across various clinical trials to improve upon this standard, such as replacement of bortezomib with carfilzomib or daratumumab, and quadruplet combinations. He then discusses if a cure is really feasible for MM, and highlights some key considerations for a true cure; when treatment is given for a finite time and the disease never returns. He concludes with his recommendations for assessing MM cure in future trials.
Treating elderly and frail patients with MM: Cure versus disease control
Vincent Rajkumar's slides are available as a downloadable resource below.Download the slides here!
Find below links to the other talks from the symposium:
'Does 'cure' have a different meaning in MM?' presented by Mohamad Mohty.
'Is the treatment of high-risk smoldering multiple myeloma (SMM) the way for achieving the cure?' presented by María-Victoria Mateos.
'Is transplantation still relevant? If yes, in which context?' presented by Sagar Lonial.
'Roundtable discussion' with María-Victoria Mateos, Mohamad Mohty, and Sagar Lonial.
MASTER trial | Monoclonal antibody-based quadruplet regimen (Dara-KRd) with MRD–based response-adapted therapy in patients with NDMM
Summary of Abstract #860 presented at ASH | Monoclonal antibody-based quadruplet regimen (daratumumab-KRd) with...
Is the treatment of high-risk SMM the way for achieving the cure?
During the 7th World Congress on Controversies in Multiple Myeloma (COMy), the Multiple Myeloma Hub hosted its first Satellite Symposium: Should 'cure' be the goal for multiple...
Subscribe to get the best content related to multiple myeloma delivered to your inbox